To The Moon

Tesla China has raised the price for all Model Y by 5,000 yuan on April 1, according to the latest price on Tesla China website. Price of Model Y Base Model in China rises to 263,900 yuan from 258,900 yuan previously. Price of Model Y Long Range in China rises to 304,900 yuan from 299,900 yuan previously. Price of Model Y Performance in China rises to 368,900 yuan from 363,900 yuan previously.

$Reddit(RDDT)$ Hot to trade, market will hot🤗🤗

$Gold Futures(APR4) (GCmain.US)$ teases record-highs in electronic trading Wednesday Gold showed little reaction in the immediate aftermath of the U.S. Federal Reserve's decision Wednesday afternoon to leave interest rates unchanged and maintain its forecast of three rate cuts this year. Then prices for the precious metal rallied toward fresh record highs. The Fed kept its benchmark rate unchanged at a range of 5.25%-5.5%, as expected, but the markets "let out big sighs of relief that the expected rate cuts for this year didn't fall from three to two," said Brien Lundin, editor of Gold Newsletter. The issue now is if those three cuts, which were well below investors' expectations at the beginning of the year, will now be "compressed into a shorter period of time," he said. "This will exace

The Zhitong Finance App learned that, according to reports, the American electric vehicle startup FSR.US (FSR.US) is planning to file for bankruptcy due to Ocean SUV's mechanical problems and lack of capital. Just two weeks ago, the company issued a warning about its ability to continue operating. Sources said Fiske has hired FTI Consulting and Davis Polk law firm to assist him in filing the application. Following the news, Fiske's stock price plummeted 46% after the market on Wednesday. At the end of last month, Fiske announced preliminary results for the fourth quarter, with a loss of 1.23 US dollars per share and total revenue of 200.1 million US dollars, a sharp drop compared with the same period last year. At the time, the company said it would be forced to reduce investment in produc

$Dell Technologies (DELL.US)$ Inc. has seen the future of computing, and it increasingly is AI instead of PC. Dell's stock (DELL) jumped 17% in extended trading Thursday after the company put up quarterly results that eclipsed Wall Street's expectations. It also announced a 20% increase in its annual cash dividend, to $1.78 per share The personal-computer company, fueled by a surge in demand for AI servers, reported fiscal fourth-quarter net income of $1.16 billion, or $1.59 a share, compared with net income of $606 million, or 84 cents a share, in the same quarter a year ago. Adjusted earnings were $2.20 a share. Net revenue slumped 11% to $22.3 billion from $25 billion in the year-ago quarter. Dell Chief Operating Officer Jeff Clarke noted $800 million in AI-server shipments during a con

Though the Federal Reserve stopped raising interest rates last summer, it is quietly tightening monetary policy through another channel: shrinking its $7.7 trillion holdings of bonds and other assets by around $80 billion a month. Now that, too, may change. Fed officials are to start deliberations on slowing, though not ending, that so-called quantitative tightening as soon as their policy meeting this month. It could have important implications for financial markets. The Fed can shrink its holdings by selling bonds or, as it has preferred, allowing bonds to mature and "run off" its balance sheet without buying new ones. Runoff increases the supply of bonds that investors must absorb, putting upward pressure on long-term interest rates. Slowing runoff reduces that upward pressure. But wher

A spot Bitcoin ETF could be approved as soon as this week, and many believe a selloff could follow. Ark Invest's Cathie Wood is taking the other side of that bet. What To Know: Bitcoin has rallied approximately 70% over the last three months, largely driven by spot ETF approval optimism. The Securities and Exchange Commission is now expected to approve an ETF this week. The SEC, actually after denying, denying a number of times, started asking questions, very good questions," Wood said Monday on CNBC's "Fast Money Halftime Report." The change in behavior from the SEC suggests that approval is nearing. Given the significant gains in anticipation of the approval, many believe the actual approval could be a sell-the-news event, Wood explained. I think so many people are expecting now a sell o

Stock investors have gotten off to a wobbly start to the new year, hobbled by shifting expectations on the timing and extent of Federal Reserve interest-rate cuts in 2024. All three major U.S. stock indexes snapped a nine-week winning streak on Friday, after unexpectedly strong December job gains prompted traders to briefly pull back on the chances of a March rate cut. The $S&P 500 Index(.SPX.US)$ and $Nasdaq Composite Index(.IXIC.US)$ also failed to stage a Santa Claus Rally from the five final trading days of 2023 through the first two sessions of 2024, as questions grew about the market’s multiple rate-cuts view. It all adds up to a glimpse of what might be in store for investors in the year ahead. Already, the so-called “January effect,” or theory that stocks tend to rise by more n

The Federal Reserve Bank of St. Louis said Evince Asset Management co-founder Alberto G. Musalem will be its next president and chief executive officer in April, succeeding Jim Bullard, who resigned from the role in July 2023. Musalem, who was a chief executive officer and co-chief investment officer of Evince, will be a voting member of the Federal Open Market Committee in 2025, rotating with other regional reserve bank presidents, St. Louis Fed said in a press release. He will fulfill the remainder of Bullard’s current five-year term that ends on Feb. 28, 2026. He will then be considered for reappointment under a process established by the Federal Reserve Board of Governors for all Reserve bank presidents, according to the press release He will participate in FOMC meetings after taking

Biotech M&A is back in a big way—and biotech stocks are benefiting from it. The industry had a tough year. The equal-weighted SPDR S&P Biotech ETF, which trades under the ticker symbol $SPDR S&P Biotech ETF(XBI.US)$, has gained 5.6% so far this year, while the market capitalization-weighted iShares Biotechnology ETF, which trades as $iShares Biotechnology ETF(IBB.US)$, has risen 1.9%. Both are well behind the S&P 500’s 24% rise. And both look much better now than they did less than two months ago. Through the end of October, IBB had dropped 13%, while XBI had tumbled 20%. Since then, they’ve both rallied, with IBB up 18% through Friday’s close, and XBI up 32%. That makes sense. Many biotech stocks, particularly small ones, are reliant on borrowed capital to conduct research